Axsome Therapeutics (AXSM) Stock Forecast & Price Target

Axsome Therapeutics is favorably positioned by Auvelity’s strong commercial traction, with 3Q26 sales of about $207.6 million, 302,000 prescriptions, and improving gross-to-net dynamics that support an expanding launch in both MDD and Alzheimer’s agitation. The company’s outlook is further strengthened by a diversified, clinically de-risked CNS pipeline, including AXS-12’s May 1, 2027 PDUFA and multiple phase III readouts in 2027, which provide meaningful upside optionality beyond the lead product. Financially, SG&A was controlled at about $203 million, cash was $313.9 million, and management indicated funding into cash-flow positivity based on the current operating plan, reinforcing the view that growth can continue without near-term balance-sheet stress.

Axsome Therapeutics is viewed negatively because its valuation and growth depend heavily on a narrow set of assets, especially Auvelity, while pipeline setbacks, slower commercialization, or weak conversion in ADA could quickly impair revenue. The company also faces persistent regulatory, manufacturing, and financing risks, plus intense competition from cheap generics, larger pharmas, and new entrants across CNS indications, which may force ongoing concessions and limit margin expansion. Even where approved products have traction, the cited data point to fragility: Sunosi sales were $33.8M in 2Q26 despite flat sequential growth, Symbravo generated only $2.3M in 2Q26 with payer coverage near 57%, and AXS-12 competes against materially stronger orexin data.